Newspaper advertisement pertaining to the loss of Share Certificates.

SARASWATI COMMERCIAL (INDIA) LTD. Regd.Off.:209-210, Arcadia Building, 2nd Floor, 195, Nariman Point, Mumbai-400021. Tel:40198600, E-mail:saraswati.investor@gcvl.in, Web:www.saraswaticommercial.com CIN:L51909MH1983PLC166605 Date: 23rd October, 2026 Corporate Relationship Department BSE Limited P. J. Towers, 25th Floor, Dalal Street, Mumbai – 400001 Ref: Scrip code: 512020 Dear Sir / Madam, Sub: Newspaper advertisement pertaining to loss of Share Certificates Pursuant to SEBI Circular No. HO/38/13/11(3)2025-MIRSD-POD/I/1102/2025 dated December 24, 2025, regarding the simplification of the procedure for issuance of duplicate share certificates, we hereby inform you that the Company has received a request from a shareholder, through its Registrar and Transfer Agent (RTA), for the issuance of a duplicate share certificate and credit of the corresponding shares to the shareholder's demat account, in lieu of the original share certificate reported as lost/misplaced. In compliance with the applicable regulatory requirements, the Company has published a newspaper advertisement on 23rd October, 2026, in Business Standard having circulation in whole of India and Mumbai Lakshadeep newspaper circulating in Mumbai, regarding the aforesaid request. Copies of the published advertisements are enclosed herewith for reference. This is for your information and records. Thanking You, Yours Faithfully, For Saraswati Commercial (India) Limited Avani Sanghavi Company Secretary & Compliance Officer Membership No.: A29108 Encl: a/a. NOTICE/SUMMONSTOAPPEARINPERSONBEFORETHEHON’BLEARBITRATOR TheCapital,1802/1901,PlotNo.C-70, GBlock,BandraKurlaComplex, (U/s84oftheMulti-StateCo-operativeSocietiesAct,2002) Bandra(East),Mumbai400051. C/o.BharatCo-op.Bank(Mumbai)Ltd. Tel:+912266932000; PlaceofArbitration:GeeseeCo-op.HousingSocietyLtd.,Opp.VidyanagariUniversityComplex,Kalina,Santacruz(East),Mumbai–400098 PfizerProductsIndiaPrivateLimited Fax:+912226540274; CIN:U24230MH1996FTC148003 Email:contactus.india@pfizer.com WHEREASBHARATCO-OP.BANK(MUMBAI)LTD.,hasfiledClaimApplicationagainstthefollowingdefaulterbeforeundersignedbeingArbitratorappointedby PUBLICNOTICE RegistrarofCo-operativeSocieties,Maharashtra,Puneu/s84ofMultiStateCo-operativeSocietiesAct,2002forrecoveryofloandues. (UnderParagraph19oftheDrugs(PricesControl)Order,2013) YouareherebysummonedthroughthispublicationtoappearbeforeaforesaidTribunalinpersonorthroughanAdvocateordulyAuthorisedRepresentativeon PursuanttotheNationalPharmaceuticalPricingAuthorityOrderS.O. the04thdayofNovember,2026at12:00Noonorsoonthereafter,whenmatteriscalledouttoanswertheclaiminthesaiddispute. 5690(E)dated17October2026onTradeMarginRationalizationof S.N. Dispute/CaseNo. Opponent non-scheduledanti-cancerdrugs,PfizerProductsIndiaPrivateLimited hasrevisedtheMaximumRetailPrice(MRP),inclusiveofalltaxes,of 1. AR/BCB/RJK/SNP/1675/2026 1. PrincipalBorrower: thefollowingproductswitheffectfrom09November2026: BharatCo-op.Bank(Mumbai)Ltd., ...Claimant Mrs. Shivani Manoj Kapoor, Prop. Of M/s. V/s. National Electrical & Engineering Consultant Sr. Previous RevisedMRP(Rs.) Mrs.ShivaniManojKapoor,Prop.OfM/s.NationalElectrical&EngineeringConsultant havinglastknownresidentialaddressesatFlat No. ProductandPack Formulation MRP(Rs.) InclusiveAlltaxes ...Opponent No. 1, Darpan Residency, Taluka Manvel, Inclusive –Effectivefrom Alltaxes Nov9th,2026 ClaimAmount:(i)Rs.4,99,706/- ason28.02.2026withinterest@15.90%p.a.inclusiveof District Pune – 412 106 and B/502, Laxmi penalcharge@2%p.a.withcompoundedmonthlyrestsonprincipaloutstanding ofRs. GreenCountySociety,KondhaweDhawadeN. 1. AROMASIN25mg. Exemestane 6,056.47 5,640.00 2,60,000/-from01.03.2026underLoanAccountNo.008313100000042,(ii)Rs.4,96,545/- as V.,Shivane,Pune–411023 Tablet-1×15blister on18.02.2026withinterest@15.90%p.a.inclusiveofpenalcharge@2%p.a.with 2. CRIZALK200mg Crizotinib 1,10,529.60 1,03,220.00 compoundedmonthlyrestsonprincipaloutstandingofRs.2,17,951/-from19.02.2026underLoan Capsule-6×10blisters AccountNo.008333510000661&(iii)Rs.48,030/- ason28.02.2026withinterest@15.90%p. 3. CRIZALK250mg Crizotinib 1,17,251.92 1,09,500.00 a.inclusiveofpenalcharge@2%p.a.withcompoundedmonthlyrestsonprincipaloutstandingof Capsule-6×10blisters Rs.20,753/-from01.03.2026underLoanAccountNo.008334010000016 &cost. 4. INLYTA1mgTablet Axitinib 17,214.13 16,095.00 TAKENOTICEthat,indefaultofyourappearanceontheday,timeandplaceasmentionedhereinabove,thedisputewillbeheardanddeterminedinyour -2×14blisters absence. GivenundermyhandandthesealoftheTribunal 5. INLYTA5mgTablet Axitinib 86,074.74 79,890.00 -2×14blisters Date: 08.10.2026 Sd/- 6. PALBACE75mg Palbociclib 22,992.19 21,640.00 Place:Mumbai JusticeR.J.Kochar Tablet-3×7blisters ArbitratorC/o.BharatCo-op.Bank(Mumbai)Ltd., 7. PALBACE100mg Palbociclib 22,992.19 21,640.00 GeeseeCo-op.HousingSocietyLtd.,Opp.VidyanagariUniversityComplex, Tablet-3×7blisters Kalina,Santacruz(East),Mumbai-400098 8. PALBACE125mg Palbociclib 22,992.19 21,640.00 Tablet-3×7blisters Pricesofallotherproductsremainunchanged.Youmayrefertothecompleteand ADDENDUMTOPUBLICNOTICE–SIXTHE-AUCTIONDATED29.09.2026 PUBLICNOTICE Wc stu aer tr ere e dn qt aup ber oso t vd esu ,toc et c ffkp eisr ci t tc s ie v, erli es 0tt a 9o il Nn er ow s v, ew h mow s b. p ep i rtf ai 2z l 0se 2r a. 6nco .d.i cn o. nsumerstonotetherevisedMRPs E-mA ais lip dI eV :r iR vInC rcsL lo .lL l iv qIM e unI iT dcE ay tD a ionU ndN @BD gaE mnR k ar iL lu .I cQ p otU c mI yD ,CA woT wdIO we .N , iv2 r0 c1 l.6 aN S nho dt aic ree s dis ib se tih a ne r cir n te ig vb ey Cg ei r Nv te i ofin .cat th e 6a s 2t 12N2 06 o 60 . 524E 56q 8u 9i 5 tt oy 0 ForPfizerProductsIndiaPrivateLimited, ADDENDUM 621206784offacevalue02/-eachunder Sd/- SaleofAssetsunderInsolvencyandBankruptcyCode,2016 folioNo.70921014ofLarsen&ToubroLtd Place:Mumbai PrajeetNair Inrespectofauctionsalenoticeissuedbytheundersignedon29.09.2026forsalethroughe-auctionof standinginthenameofUdayShankarrao Date:23October2026 AuthorisedSignatory IVRCLLimited,thetimelinesofthesaidprocessarerevisedasunder.TheSalewillbedonebythe MankarandMrs.NishitaUdayMankarhas undersignedthroughtheE-Auctionplatformatthewebportalhttps://ibbi.baanknet.com/eauction-ibbi/home been Lost or mislaid and the undersigned Briefparticularsofthesaleareasfollows: has/haveappliedtotheCompanytoissue Description Asperthe duplicatecertificatesforthesaidshares. AuctionNotice Anypersonwhohasanyclaiminrespectof CategoryA-SaleofCorporateDebtorasaGoingConcern: 23.10.2026 thesaidsharesshouldwritetoourRegistrar, AssetSet1:SaleofCorporateDebtorasagoingconcernon"ASIS at11.00AMto KFIN TECHNOLOGIES LTD, Selenium WHEREIS","ASISWHATIS","WHATEVERTHEREIS"AND"WITHOUT 01.00PM TowerB,Plot31-32,Gachibowli,Financial RECOURSEBASIS" District, Nanakramguda, Hyderabad, Telangana-500032 within one month from CategoryB-SaleofInvestmentsoftheCD(Incasenobidsarereceivedfor thisdateelsethecompanywillproceedto auctionunderCategoryA) issueduplicatecertificates. AssetSet2:SaleofInvestmentsoftheCDinSalemTollwaysLimited(SPV) UdayShankarraoMankar beingpartofassetsoftheCDon"ASISWHEREIS","ASISWHATIS", &NishitaUdayMankar "WHATEVERTHEREIS"AND"WITHOUTRECOURSEBASIS" Nameofshareholder AssetSet3:SaleofInvestmentsoftheCDinKumarpallayamTollways Date:22.10.2026 Limited(SPV)beingpartofassetsoftheCDon"ASISWHEREIS","ASIS Place:Mumbai WHATIS","WHATEVERTHEREIS"AND"WITHOUTRECOURSEBASIS" CHEMFAB ALKALIS LIMITED CIN:L24290TN2009PLC071563 Regd.Office:TeamHouse,GSTRoad,Vandalur,Chennai600048. Website:www.chemfabalkalis.com Email:ccalcosecy@ccal.in PhoneNo:+914422750323 FaxNo:+914422750860 NOTICETOTHESHAREHOLDERSOFTHECOMPANY SPECIALWINDOWFORRE-LODGEMENTOFTRANSFERREQUESTSOFPHYSICALSHARES In accordance with SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026, shareholders are hereby informed that a special window has been opened for a period of one year from February 05, 2026 to February 04, 2027 for transfer-cum-dematerialisation of physical securities which were sold/purchase [Showing first 8,000 characters — download PDF for full document]